Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
– Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide – Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, is seeking people who stutter to … Read more